BioPharm Systems Unveils Study Data Mapper to Simplify the Preparation and Reporting of Clinical Data
BioPharm Systems, a global IT consulting organization specializing in Oracle's clinical trial, data management, safety, and pharmacovigilance systems, today unveiled Study Data Mapper, a new web-based software application that allows users to map from one data structure to another through a user interface and spreadsheets without any need for programming.
Specifically developed for the life sciences industry,Study Data Mapper simplifies the process of preparing standard data structures, such as CDISC SDTM, in a regulatory-compliant manner. The solution automatically generates the portable SAS program code to implement an organization's transformations through the interactive mapping of metadata from source systems to standard structures. Since all of the mappings are stored in a metadata repository, the components and mapping used in one clinical trial or project can be reused and modified for others. The result is that the preparation of data becomes a specification process rather than a programming exercise.
"The overall efficiency of preparing clinical trials and programs for reporting and analysis can be greatly improved with Study Data Mapper," said Michael Grossman, vice president of clinical data warehousing and analytics, BioPharm Systems. "The solution is ideal for organizations seeking to gain a competitive edge, save time, and reduce costs."
ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology, and medical device industries, commissioned the development of Study Data Mapper, and is already using the application.
To learn more about Study Data Mapper, please call Rod Roderick at +1 877 654 0033 (U.S.) or Rudolf Coetzee at +44 (0) 1865 910200 (U.K.). You can also visit http://www.biopharm.com or e-mail info(at)biopharm(dot)com.
BioPharm Systems is a Gold level member of Oracle PartnerNetwork (OPN) and an Oracle Accelerate solution provider. The company has achieved Specializations in Oracle Argus Safety Suite, Oracle Life Sciences Data Hub, and Oracle Accelerate for Midsize Companies.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
